Introduction {#Sec1}
============

Obesity and diabetes represent dire threats to public health. In 2014, the WHO estimated that there were 1.9 billion overweight and 600 million obese people worldwide \[[@CR1]\], representing 39% of the global population \[[@CR1]\]. Obesity has direct links to hypertension, cardiovascular disease, certain types of cancers and, most predominantly, type 2 diabetes \[[@CR2], [@CR3]\]. In 2014, there were 422 million people with diabetes (8.5% of the global population) \[[@CR4]\] and this number is expected to rise to 592 million by 2035 \[[@CR5]\].

While often concurrent in a single person, each of these diseases is individually managed and this is likely to continue until the intransigence of obesity is successfully addressed. Once a person is overweight or, worse, obese, it is extremely difficult to permanently reverse the weight gain. Lifestyle interventions, anchored on diet and exercise, typically provide a small, short-lasting weight loss \[[@CR6]\]. At the other extreme, bariatric surgeries are highly effective in reducing body weight and improving glucose tolerance in most individuals \[[@CR7], [@CR8]\]. However, such intervention is highly invasive, has considerable risk and is irreversible and expensive. Therefore, surgery is recommended only for individuals who are severely obese (BMI \> 40 kg/m^2^) or who have a BMI of 35--40 kg/m^2^ together with severe comorbidities such as cardiopulmonary disease or diabetes \[[@CR9]\].

For people who do not meet the eligibility criteria for bariatric surgery and who fail to maintain weight loss through lifestyle interventions, pharmacotherapy is the only remaining option. Current federally approved pharmacotherapies are reported to result in 5--15% body weight loss \[[@CR10]\]. Anti-obesity and glucose-lowering pharmacotherapies predominantly exert their actions by inducing satiety (liraglutide, setmelanotide, lorcaserin, pramlintide, sibutramine) or by inducing malabsorption of nutrients (orlistat). When sustained, this degree of weight loss can provide meaningful improvements in metabolism and lipid management \[[@CR11]\]. However, these therapies are commonly accompanied by adverse gastrointestinal and cardiovascular effects that limit their use \[[@CR12]\]. The ultimate goal is to identify medicinal therapy that approaches the effectiveness of bariatric surgery without its associated complexities, adverse effects or financial burden.

It is logical that improved efficacy can be achieved by combining multiple metabolic actions within a single therapy; indeed, there is precedent for this \[[@CR13]\]. The challenge has been to minimise and balance the pharmacology to select a combination that maximises the benefit without risk of irreversible toxicity, as historically experienced in co-therapy with fenfluramine and phentermine. In this review, we discuss the discovery and development of the first rationally designed approach to unimolecular co-agonism, which recruits the well-established pharmacology of glucagon-like peptide 1 (GLP-1) and, counterintuitively, glucagon.

Physiology, pharmacology and clinical relevance of GLP-1 {#Sec2}
========================================================

GLP-1 is a peptide hormone produced within the L cells of the intestine. GLP-1 is derived from proglucagon, and proteolytic processing results in the biologically active form, consisting of 30 amino acids. There is some ambiguity in the literature when numbering the amino acids within GLP-1, as the prohormone is synthesised with 37 amino acids. The endogenous cleavage of the first six residues results in the biologically active peptide, which represents GLP-1 (7--36) amide. Consequently, two numbering systems have been used where the seventh amino in the precursor and the first in active hormone are the same. In this text, we use the numbering whereby the amino acids that constitute active GLP-1 represent positions 1--30 and are the same as 7--36 in the precursor.

GLP-1 is secreted in response to nutrient ingestion, especially in response to meals high in fat and carbohydrates \[[@CR14]\]. GLP-1 functions to delay gastric emptying, stimulate insulin secretion and mediate satiety in the central nervous system (CNS), all actions that are beneficial to individuals with obesity and type 2 diabetes. In type 2 diabetes, preprandial administration of native GLP-1 reduces plasma glucose and improves glucose tolerance \[[@CR15]\]. However, due to its short circulating half-life, native GLP-1 is ill-suited for chronic therapy \[[@CR14]\]. The short half-life (1--2 min in humans) results from dipeptidylpeptidase-IV (DPP-IV) proteolysis by which the N-terminal dipeptide is rapidly removed, inactivating GLP-1. GLP-1 is also cleared relatively quickly by renal filtration \[[@CR16]\]. To effectively use GLP-1 as a drug, several modifications have been made to address proteolysis and clearance. Substitution with the non-native amino acid aminoisobutyric acid at position 2 confers resistance to DPP-IV degradation \[[@CR17]\]. Other chemical modifications include increasing the size of the hormone or promoting non-covalent attachment to serum albumin, thus extending the plasma circulation time \[[@CR18], [@CR19]\].

An alternative approach to enable oral administration employs DPP-IV inhibitors to preserve endogenous GLP-1. Currently, there are several registered DPP-IV inhibitors, including sitagliptin, saxagliptin and linagliptin \[[@CR20]\]. Studies comparing DPP-IV inhibitors with GLP-1 receptor (GLP-1R) agonists have shown greater weight loss and reduction in glucose excursions in individuals treated with GLP-1R agonists \[[@CR20]\]. This reflects the ability to more intensively supplement physiological levels with GLP-1R agonists, rendering them the more powerful approach for treating obesity and type 2 diabetes. There are six GLP-1-based medicines currently approved by the US Food and Drug Administration (FDA): exenatide, lixisenatide, liraglutide, semaglutide, dulaglutide and albiglutide (Table [1](#Tab1){ref-type="table"}). Each of these has been optimised by a specific method to extend the duration of action of GLP-1 following a single injection.Table 1GLP-1-based mono-agonists and poly-agonists in preclinical development or used clinically for obesity and type 2 diabetes therapyDrugCompanyTargetPhaseAdministrationExenatide (Byetta)AstraZenecaGLP-1RRegisteredSC, twice dailyExenatide (Bydureon)AstraZenecaGLP-1RRegisteredSC, weeklyLixisenatide (Lyxumia)Sanofi-AventisGLP-1RRegisteredSC, dailyLiraglutide (Victoza)Novo NordiskGLP-1RRegisteredSC, dailySemaglutideNovo NordiskGLP-1RPhase 3Oral, dailySemaglutideNovo NordiskGLP-1RPhase 3SC, weeklyDulaglutide (Trulicity)Eli LillyGLP-1RRegisteredSC, weeklyAlbiglutide (Tanzeum)^a^GlaxoSmithKlineGLP-1RRegisteredSC, weeklySAR425899Sanofi-AventisGLP-1R/GcgRPhase 1SC, dailyLY2944876/TT-401Eli LillyGLP-1R/GcgRPhase 2SC, weeklyHM12525AHanmi PharmaceuticalsGLP-1R/GcgRPhase 1SC, weeklyZP2929ZealandGLP-1R/GcgRPhase 1SC, dailyMEDI0382MedImmuneGLP-1R/GcgRPhase 1SCVPD-107Spitfire PharmaGLP-1R/GcgRPreclinicalSC, weeklyMOD-6031OPKO BiologicsGLP-1R/GcgRPhase 1SC, monthlyLiraglutide + NN9030Novo NordiskGLP-1R + GcgRPhase 1SCCpd86Eli LillyGLP-1R/GIPRPreclinicalSCZP-DI-70ZealandGLP-1R/GIPRPreclinicalSC, weeklyNN9709/MAR709Novo Nordisk/MarcadiaGLP-1R/GIPRPhase 2SC, dailyMAR423Novo Nordisk/MarcadiaGLP-1R/GIPR/GcgRPhase 1SC, daily^a^Also available as EperzanGIPR, Glucose-dependent insulinotropic polypeptide receptor; SC, subcutaneous

Exenatide (Byetta, AstraZeneca) is a synthetic version of exendin-4, a GLP-1R agonist found in the saliva of the Gila monster (*Heloderma suspectum*). Exenatide contains a glycine at position 2, rendering it less susceptible to DPP-IV degradation, and includes a C-terminal extension (CEX), which stabilises the secondary structure of the hormone, increasing its solubility in physiological buffer. These modifications extend the half-life of the hormone to 2.4 h \[[@CR18]\]. Exenatide is also available as microsphere depot formulation (Bydureon, AstraZeneca), which sustains the duration of action suitable for once-weekly administration \[[@CR21]\]. Further modifications to exenatide yielded lixisenatide (Lyxumia, Sanofi-Aventis), which has an extended C-terminus including six consecutive lysine residues. Lixisenatide is potent at the GLP-1R and has a half-life of 3--4 h \[[@CR22]\]. In clinical trials, both exenatide and lixisenatide reduced body weight by 2.0--3.8 kg and reduced HbA~1c~ levels by 0.5--1.5% (5.5--1.6 mmol/mol) \[[@CR23]--[@CR25]\]. Exenatide was approved by the US FDA in 2005 and by the European Medicines Agency (EMA) in 2006.

Unlike exenatide and lixisenatide, liraglutide (Victoza, Novo Nordisk) maintains enhanced sequence similarity to native human GLP-1. Its main modification is a C16 palmitoyl moiety covalently attached to the lysine at position 20 through a γ-glutamic acid chemical spacer. Liraglutide also includes an arginine substitution at position 28. Since liraglutide retains the native alanine at position 2, it is not directly protected from enzymatic degradation, although palmitoylation and subsequent association with serum albumin results in steric protection \[[@CR26]\]. Liraglutide was approved by the EMA in 2009 and the US FDA in 2010 as a glucose-lowering therapy and at a higher dose by the US FDA for the treatment of obesity. In individuals with type 2 diabetes, liraglutide treatment results in a weight loss of 1.3--8.6 kg and a 0.9--2.2% (9.9--24.2 mmol/mol) reduction in HbA~1c~, relative to baseline \[[@CR27]\].

Similar to liraglutide, semaglutide (Novo Nordisk) is a fatty-acylated GLP-1 analogue with a stearic-diacid at lysine position 20, linked via a di-aminoethoxy, γ-glutamic acid spacer, and an aminoisobutyric residue at position 2 to provide protection from DPP-IV degradation \[[@CR28]\]. Semaglutide has a half-life of 165 h in humans, due in part to non-covalent association with human serum albumin \[[@CR28]\]. Preclinical safety studies demonstrated no indication of pancreatitis or pancreatic inflammation in cynomolgus monkeys \[[@CR29]\]. Semaglutide has advanced to registration phase clinical trials. In patients with type 2 diabetes, semaglutide is reported to improve glycaemic control dose-dependently, decreasing HbA~1c~ levels by 1.7% (18.7 mmol/mol) vs 0.5% (5.5 mmol/mol) with placebo and 4.8 kg of weight loss vs 1.2 kg with placebo, relative to baseline. The magnitude of these effects was greater than those with open-label liraglutide in the same study \[[@CR30]\]. In addition, in a cardiovascular outcome study involving patients with type 2 diabetes, of whom more than 80% had a history of cardiovascular disease, semaglutide treatment lowered the rates of 3-point MACE (myocardial infarction, stroke and cardiovascular death) \[[@CR31]\]. Semaglutide has been developed as a once-a-week subcutaneous injection and is currently also being developed for daily oral administration.

Dulaglutide (Trulicity, Eli Lilly) consists of two fused GLP-1 analogues, with a glycine substitution at position 2, a glutamic acid substitution at position 20 and a glycine at position 30, which protect against DPP-IV degradation \[[@CR19], [@CR32]\]. The half-life of dulaglutide is greatly extended by its conjugation to the Fc fragment of human IgG4 \[[@CR18]\]. This antibody conjugation increases the molecular weight of the molecule well past the renal threshold, providing a half-life of 96 h \[[@CR18]\]. In clinical trials, dulaglutide produced a 2.3--3.0 kg body weight loss and a 0.78--1.64% (8.6--18.0 mmol/mol) reduction in HbA~1c~, relative to baseline \[[@CR33]\]. Dulaglutide was approved by the US FDA and the EMA in 2014.

Albiglutide (Tanzeum \[also available as Eperzan\], GlaxoSmithKline) is a fusion of two repeats of GLP-1 and rDNA-derived human albumin. Within the GLP-1 sequences, the alanine at position 2 is substituted with a glycine residue to confer protection against DPP-IV. The half-life of this molecule is 5 days \[[@CR18]\]. Studies in individuals with type 2 diabetes revealed a 1.1--1.7 kg reduction in body weight and a 0.79--0.89% (8.7--9.78 mmol/mol) decrease in HbA~1c~ \[[@CR34]\]. Albiglutide was approved by the US FDA and the EMA in 2014.

While all of these GLP-1-based medicines demonstrate some success in lowering body weight and HbA~1c~ levels, GLP-1 and its analogues are not without unwanted side effects. The most common adverse effect is nausea. While often mild, the nausea is dose dependent and limits the use of higher doses to drive greater weight loss \[[@CR35]\]. GLP-1 therapies may also increase the risk of pancreatitis, although this concern seems to have abated in the last 2 years \[[@CR36]--[@CR39]\]. In this regard, clinical study of lixisenatide in individuals with type 2 diabetes and acute coronary syndrome did not reveal an association with pancreatitis \[[@CR40]\]. Similarly, recent long-term studies of liraglutide and semaglutide, focusing on cardiovascular outcomes in individuals with type 2 diabetes, reveal a similar incidence of pancreatitis between groups treated with the GLP-1R agonists and placebo \[[@CR31], [@CR41]\].

Physiology, pharmacology and clinical relevance of glucagon {#Sec3}
===========================================================

Glucagon is a peptide hormone secreted by the alpha cells of the pancreas in response to fasting or hypoglycaemia \[[@CR42]\]. Its primary physiological role is to raise blood glucose levels by inhibiting insulin secretion and by stimulating hepatic glucose production. Glucagon secretion is reciprocally inhibited by insulin action. Therefore, when insulin resistance occurs (as in obesity and type 2 diabetes) or there is complete absence of endogenous insulin (as in type 1 diabetes) there is relative hyperglucagonaemia. This hyperglucagonaemia is observed in most forms of diabetes, in humans and animal models \[[@CR43]--[@CR45]\].

Glucagon is currently available as an injectable treatment for hypoglycaemia, although it is not widely used given its complex method of administration. Glucagon in powder form must be solubilised immediately before injection, a cumbersome process made more difficult by the symptoms of hypoglycaemia, which include mental confusion or even unconsciousness \[[@CR46]\]. Recent advances have altered the solubility of glucagon by substituting more hydrophilic residues into the sequence or by use of the CEX \[[@CR47]\]. A more stable, physiologically buffered glucagon solution is additionally attractive for potential use in a bi-hormonal pump for treatment of type 1 diabetes.

Owing to glucagon's hyperglycaemic and insulin-suppressing effects, the glucagon receptor (GcgR) has historically been a prime target for pharmacological suppression rather than activation. Genetically engineered mice without a functional GcgR exhibit lowered blood glucose levels and severe fasting-induced hypoglycaemia \[[@CR48]\]. Furthermore, mice made diabetic by streptozotocin (STZ) administration, but genetically deficient for the GcgR, display normal glucose tolerance \[[@CR49]\]. Small-molecule antagonists of the GcgR have reduced glycogen breakdown in vitro \[[@CR50]\], and the use of antagonistic antisense oligonucleotide directed to the GcgR in *ob*/*ob* and *db*/*db* mice resulted in reduced blood glucose \[[@CR44], [@CR51]\]. Similarly, GcgR antagonists have been reported to reduce blood glucose in STZ-induced diabetic rats \[[@CR52]\]. In metabolically healthy men, an infusion of Bay 27-9955, one of the first small-molecule GcgR antagonists, lowered blood glucose in response to a glucagon challenge \[[@CR53]\]. Interestingly, recent clinical studies have confirmed the glucose-lowering effects of GcgR antagonism in individuals with type 2 diabetes \[[@CR54], [@CR55]\]. However, uncertainties persist regarding the prospects for adverse liver effects that might be inherent to the mechanism of action, as stabilisation of hepatic steatosis would be unwelcome.

In addition to effects on glucose homeostasis, glucagon has both catabolic and thermogenic actions. In humans, intravenous administration of glucagon decreases plasma lipids, cholesterol and arachidonic acid through altered metabolic partitioning \[[@CR56]\]. Glucagon administration also decreases hepatic triacylglycerol synthesis in rats \[[@CR56]\] and stimulates hormone-sensitive lipase in human and rat white adipocytes to promote lipolysis and the release of NEFA \[[@CR57], [@CR58]\]. These fatty acids freely circulate and can be accessed by heart, skeletal muscle, kidneys and liver \[[@CR56]\]. The kidneys and liver metabolise the fatty acids, producing ketone bodies as common metabolites \[[@CR56]\]. These biological actions define the counter-balancing catabolic role that glucagon serves relative to insulin's anabolic action.

Glucagon also stimulates energy expenditure. In both rats and humans, infusion of glucagon results in increased oxygen consumption \[[@CR59], [@CR60]\]. In vitro studies suggest that this effect is mediated by brown adipose tissue (BAT) \[[@CR61]\]. It has also been shown that cold exposure increases plasma glucagon levels, suggesting a role for glucagon in non-shivering thermogenesis \[[@CR62]\]. Supporting the role of glucagon in increasing BAT thermogenesis, it has been shown that glucagon administration enhances BAT temperature \[[@CR63]\]. However, recent evidence that glucagon increases energy expenditure independently of BAT activation in humans \[[@CR64]\] indicates that alternative mechanisms such as futile substrate cycling \[[@CR65]\] may underlie glucagon's thermogenic properties.

In isolation, the catabolic and thermogenic actions of glucagon would be beneficial to individuals who are obese or have type 2 diabetes but these actions are inherently paired with the undesirable stimulation of gluconeogenesis and glycogenolysis. Considering the beneficial effects of GcgR antagonists on glycaemia \[[@CR66]--[@CR68]\], it would seem counterintuitive to employ agonism in a therapy for obesity and, certainly, diabetes. Therefore, to safely harness the attractive catabolic and thermogenic effects of glucagon for treating metabolic disease, a counter-balancing therapy that selectively opposes the risk for glucagon-induced hyperglycaemia is required. In the first undertaking toward that goal, GLP-1 was explored as an ideal pharmacological partner, leading to the purposeful discovery of the first GLP-1R/GcgR co-agonists.

Co-targeting the GLP-1R and GcgR for obesity treatment {#Sec4}
======================================================

Unimolecular GLP-1R/GcgR co-agonists for obesity treatment {#FPar1}
----------------------------------------------------------

The search for single molecules and, with recently developed high-tech approaches, single mechanisms for treatment of obesity is ongoing. Unfortunately treatment of complex chronic diseases such as obesity has often proven recalcitrant to attempts to attain the desired health benefits \[[@CR69]\]. Combination treatments have become common practice in the treatment of type 2 diabetes, hypertension and other diseases associated with advanced age. It is anticipated that obesity will prove no different, with simultaneous activation of anorectic and thermogenic pathways producing meaningful and sustained clinical outcomes. Mixtures of individual medicines complicate drug development and the magnitude of the problem is virtually overwhelming when there are more than two active entities. A promising pharmacological strategy to circumvent this has been made in the treatment of obesity and the metabolic syndrome, via the integration of multiple mechanisms within a single molecule \[[@CR18], [@CR69]\]. A unimolecular approach can provide additional benefits relative to co-administration of individual medicines as there is a single pharmacokinetic profile and metabolic fate and the potential for multiple actions at a single cellular target is more likely. Finally, a major objective along with efficacy is safety and, when compared with separate drugs functioning through a single mechanism, there is the promise of reduced toxicity through a less aggressive effect associated with any one single mechanism of action. Recently developed unimolecular GLP-1R/GcgR co-agonists have superior preclinical efficacy to currently prescribed monotherapies in the treatment of obesity.

GLP-1 and glucagon promote weight loss through distinct mechanisms of action {#FPar2}
----------------------------------------------------------------------------

GLP-1 is believed to act predominantly in the hypothalamus to induce satiety, whereas the weight-lowering effects of glucagon are mostly driven by its lipolytic and thermogenic effects in liver and the adipose tissue \[[@CR56]\]. Notably, these peptides have conflicting effects on glucose homeostasis. While GLP-1 lowers blood glucose levels by promoting insulinotropic actions \[[@CR70]\], glucagon promotes hyperglycaemia by stimulating hepatic glucose production \[[@CR56]\]. It was hypothesised that integration of these opposing actions into a single molecule might minimise the inherent diabetogenic risk of GcgR agonism. Importantly, GLP-1 and glucagon act through structurally related receptors and both peptides exhibit similar amino acid N-terminal sequences, a domain essential for proper interaction with their receptors. Taken together, the metabolic actions of GLP-1 and glucagon, as well as their structural similarities, inspired the search for single-molecule GLP-1R/GcgR co-agonists as potential candidates for obesity treatment.

A variety of unimolecular GLP-1R/GcgR dual agonists were built using the glucagon amino acid sequence as a template. These glucagon-based chimeric peptides were generated by amino acid substitutions to the glucagon sequence aimed at increasing potency at the GLP-1R and conferring balanced co-agonism at both receptors. Additionally, a 40 kDa polyethylene glycol (PEG) polymer was incorporated at position 24 to extend duration of action and reduce frequency of administration. Amino acid substitution at position 2 eliminated DPP-IV proteolysis \[[@CR17]\]. Preclinical studies in diet-induced obese (DIO) mice showed that once-weekly administration of the PEGylated GLP-1R/GcgR co-agonist for 1 month dramatically lowered body weight, compared with vehicle treatment \[[@CR17]\]. More importantly, the magnitude of improvement in body weight resulted from increased energy expenditure and decreased food intake, which led to a remarkable loss of fat mass. Furthermore, chronic intervention with the dual-action peptide improved lipid metabolism and hepatic steatosis when compared with a chemically matched peptide having high selectivity for the GLP-1R. Contrary to expectations, glycaemic control was also improved after chronic treatment with the GLP-1R/GcgR co-agonist, which implies that GLP-1 activity protected against glucagon-induced hyperglycaemia \[[@CR17]\]. Complementary pharmacological studies in mice lacking the GLP-1R corroborated the essential role of GLP-1R agonism in improving glycaemic control and confirmed that the metabolic improvement associated with co-agonist treatment was due to concerted activation of both receptors \[[@CR17]\].

The promise of GLP-1R/GcgR co-agonism in the treatment of obesity was highlighted in studies exploring its effect in concert with leptin therapy. Leptin, an adipocyte-derived hormone known to regulate energy homeostasis, acts in the brain to control energy and glucose metabolism \[[@CR71]\]. The discovery of leptin generated great hopes for an effective anti-obesity drug. However, it was found that obese people are hyperleptinaemic, develop central leptin resistance and are unresponsive to leptin therapy \[[@CR72]\]. It has recently been shown that a PEGylated GLP-1R/GcgR co-agonist could restore leptin sensitivity in DIO mice chronically maintained on a high-fat diet \[[@CR73]\], and this may constitute one of the inherent weight-lowering actions of the co-agonist. Regarding the mechanism of action of the dual agonist, it is well-appreciated that GLP-1 acts centrally and in peripheral tissues to regulate energy and glucose homeostasis \[[@CR74]\]. The appetite-suppressing effect of GLP-1 is mediated by its action in the brain, whereas its glucose-lowering effect is mainly attributed to enhancement of glucose-stimulated insulin secretion \[[@CR74]\]. In mice lacking the GLP-1R in the CNS, GLP-1R agonism does not lower body weight but its glycaemic benefits are preserved \[[@CR75]\]. Therefore, the glycaemic improvement in animals treated with a GLP-1R/GcgR co-agonist is attributable to body-weight-independent and -dependent effects.

Like GLP-1, glucagon acts centrally and peripherally to regulate energy and glucose homeostasis. Glucagon suppresses food intake by acting in the brain \[[@CR76]\] and increases energy expenditure by stimulating thermogenesis in peripheral tissues \[[@CR74]\]. Hence, the action of dual GLP-1R/GcgR agonists likely results from a combination of central and peripheral mechanisms, at multiple target tissues. The major metabolic actions of dual GLP-1R/GcgR agonists are summarised in Fig. [1](#Fig1){ref-type="fig"}. Notably, the metabolic benefits of dual GLP-1R/GcgR agonists have also been documented in obese non-human primates, where chronic administration of a lower dose of a GLP-1R/GcgR co-agonist vs a GLP-1R mono-agonist reduced body weight and improved glucose tolerance to a greater degree \[[@CR77]\]. Additional studies in cynomolgus monkeys have confirmed the potent dose-dependent, weight-lowering effects of chronic GLP-1R/GcgR co-agonism \[[@CR78]\], supporting the translational promise of this novel balanced agonism for obesity and type 2 diabetes.Fig. 1Metabolic actions of GLP-1R agonists and GcgR agonists on key organs (brain, BAT, adipose tissue, muscle, liver, pancreas and circulation) regulating energy and glucose homeostasis and changes in metabolic variables. FAO, fatty acid oxidation; GSIS, glucose-stimulated insulin secretion

Preclinical trials demonstrate that this co-agonist improves glucose tolerance, indicating that the GLP-1 activity can successfully buffer the hyperglycaemic potential of GcgR agonism. Nevertheless, these co-agonists must be carefully monitored as a loss in GLP-1R activity could lead to excessive glucagon-mediated deleterious effects on glucose control. It is especially important to confirm that this therapy is safe and effective in conditions of insulin insensitivity and impaired insulin secretion. While the long-term consequences of GLP-1R agonism are now emerging, similar studies will be required for glucagon, particularly in the context of simultaneous GLP-1R agonism.

Parallel to the development of the glucagon-based co-agonists, investigations from an independent research group validated the concept, reporting anti-obesity properties for a chemically modified version of the gut hormone oxyntomodulin (OXM) \[[@CR79]\]. OXM is a peptide hormone released postprandially from the intestinal L cells. It is able to activate both the GcgR and the GLP-1R but with much reduced potency relative to the native ligands. Despite its low potency at both receptors and less-certain in vivo activity at the GcgR, chronic OXM treatment decreased body weight and food intake in rodents when GLP-1R action was present \[[@CR79]--[@CR81]\]. The anorectic and thermogenic effects of OXM were also demonstrated in overweight and obese humans, where chronic administration with native OXM resulted in modest weight loss without any detectable adverse effects \[[@CR82]--[@CR84]\].

Like GLP-1, OXM is rapidly degraded in the circulation by DPP-IV. To improve the pharmacokinetic profile and further explore the therapeutic potential of such an endogenously based GLP-1R/GcgR co-agonist, a DPP-IV-resistant OXM analogue was developed by adding a [d]{.smallcaps}-stereoisomer of serine at position 2 and a cholesterol moiety to the C-terminal domain. This modified version of OXM safely improved body weight and lipid metabolism when compared with a long-acting GLP-1R agonist in DIO mice \[[@CR79]\]. Interestingly, no evidence of the hyperglycaemic effect of glucagon was detected in the OXM-treated mice. Instead, OXM treatment resulted in improved glycaemic control at a magnitude comparable with that of a selective GLP-1R agonist \[[@CR79]\]. Subsequent OXM structure--activity relationship studies identified a series of analogues with superior potency relative to the native hormone \[[@CR85]\]. Variants of OXM resistant to DPP-IV (achieved by addition of PEG \[[@CR86]\], fatty acids \[[@CR87]\], substitution of certain amino acids \[[@CR85]\] or even combined modifications \[[@CR88]\]) have been advanced to circumvent the limited clinical potential of the native peptide. Such OXM analogues hold promise for the treatment of obesity and independently support the findings with glucagon-based co-agonists.

Translational perspective for the use of dual GLP-1R/GcgR agonists for obesity {#FPar3}
------------------------------------------------------------------------------

Multiple clinical trials involving GLP-1R/GcgR co-agonists are currently underway (Table [1](#Tab1){ref-type="table"}). Triggered by the first report of successful preclinical tests \[[@CR17]\], pharmaceutical companies are strongly committed to the development of this novel therapeutic approach against obesity and type 2 diabetes. Their combined efforts represent a significant number of clinical studies, at different stages and with differing co-agonists (Table [1](#Tab1){ref-type="table"}). Results from these clinical trials are beginning to be disseminated. Recent studies by Sanofi-Aventis and Eli Lilly in phase 1 and 2, respectively, were the first to report and have stimulated further interest in the field. In these first short-term clinical trials, focused on safety and dose optimisation, the administration of two different GLP-1R/GcgR co-agonists reduced HbA~1c~ in overweight diabetic individuals, with some degree of body weight loss \[[@CR69]\]. These outcomes are preliminary but suggest that the dual GLP-1R/GcgR agonism observed in preclinical models may translate to humans. They help define the magnitude of GcgR agonism that can be tolerated in the context of GLP-1R agonism, as well as the degree of additional efficacy that it might yet be possible to achieve. Going forward, special attention should be paid to the exploration of potential unwanted effects, particularly those affecting cardiovascular health with heart rate being one of the easiest variables to monitor.

Co-administration of GLP-1 and glucagon for obesity therapy {#FPar4}
-----------------------------------------------------------

Based on the above findings and considering that GLP-1 and glucagon are registered medicines in the treatment of different aspects of diabetes, exploratory combination studies in non-diabetic overweight individuals have been carried out. It was found that acute co-infusion of low doses of GLP-1 and native glucagon reduced food intake and increased energy expenditure to a greater extent than was achieved with either peptide infused alone \[[@CR89], [@CR90]\]. There were no reported adverse effects and it was confirmed that GLP-1 prevented the diabetogenic effect of glucagon through its insulinotropic actions. While these results are certainly encouraging, they should be regarded as preliminary. Acute measurements that will require more extensive study are needed before any meaningful conclusion can be made regarding the long-term prospects for combination therapy as mixture or for a single molecule with integrated dual agonism.

Alternative multi-agonists for obesity treatment {#Sec5}
================================================

GLP-1R/GcgR dual agonists have shown impressive metabolic benefits and inspired the search for what now represents a growing class of rationally designed multi-agonists with differentiated mechanisms of action for obesity therapy. Other gut hormones, such as glucose-dependent insulinotropic polypeptide (GIP), have been utilised in dual agonists. GIP stimulates insulin secretion in response to nutrient ingestion \[[@CR14]\]. Due to sequence similarities between GLP-1 and GIP, a chimera peptide of GLP-1 residues and certain C-terminal residues of GIP activates both the GLP-1 and GIP receptor (GIPR) \[[@CR91]\]. A biweekly injection of a fatty-acylated version of this dual agonist improved body weight, glucose homeostasis and lipid metabolism in DIO mice \[[@CR91]\]. Chronic treatment with the co-agonist also improved glucose tolerance and insulin secretion in cynomolgus monkeys and humans \[[@CR91]\]. Other GLP-1R/GIPR co-agonists such as Cpd86 (Eli Lilly), ZP-DI-70 (Zealand) and NN9709/MAR709 (Novo Nordisk/Marcadia) have also been designed and tested in preclinical models of obesity and subsequently advanced to clinical trials (Table [1](#Tab1){ref-type="table"}).

In addition to dual agonists, triple agonists hold enhanced therapeutic potential for obesity and type 2 diabetes (Table [1](#Tab1){ref-type="table"}). In DIO mice, a GLP-1R/GIPR co-agonist supplemented by an injection of a GcgR agonist resulted in a greater decrease in body weight and food intake than the co-agonist alone \[[@CR92]\]. Therefore, a tri-agonist was designed, incorporating residues from GLP-1, glucagon and GIP, as well as having a stabilising CEX. The tri-agonist was tenfold more active than individual native hormones at all three receptors in vitro, and was more effective than a GLP-1R/GIPR co-agonist at lowering body weight in DIO mice \[[@CR92]\]. Following this, novel GLP-1R/GIPR/GcgR tri-agonists, achieved through antibody-based constructs, have been developed. The fusion of a co-agonist or a single gut hormone with either the light or heavy chain of the antibody palivizumab provides mixed agonists capable of potently activating two or more receptors simultaneously in a balanced manner \[[@CR93]\]. Such an antibody-based fusion protein that activates both the GLP-1R and GcgR is reported to reduce body weight in DIO mice by 12% \[[@CR93]\].

While gut-hormone-based multi-agonists have great therapeutic potential, the conceptual approach to multi-agonism is not limited to incretin hormones, or even to structurally related peptides. An intriguing avenue of research is the combination of peptides and nuclear hormones, where the peptide serves to target the latter to specific tissues and intracellular sites of action to minimise adverse off-target tissue effects. For example, it is known that oestrogen is an anorectic hormone that also promotes thermogenesis \[[@CR94], [@CR95]\]. Hence, chronic oestrogen therapy may protect against obesity and its related comorbidities. Given alone, oestrogen has oncogenic potential, particularly in gynaecological tissues, precluding its use for metabolic purposes. To minimise unwanted effects and maximise metabolic actions, a covalent conjugate of oestrogen and GLP-1 was developed. This GLP-1-mediated delivery of oestrogen to specific tissues enhanced body weight loss and improved glycaemic control and insulin sensitivity relative to either of the hormones alone in DIO mice \[[@CR96]\]. Subsequent studies documented the protective role of the GLP-1/oestrogen conjugate against the loss of pancreatic beta cells in New Zealand Obese (NZO) mice \[[@CR97]\]. Importantly, no uterine hypertrophy or tumorigenic effects were detected in mice following chronic intervention with the conjugate, demonstrating its specificity in action and relative safety in comparison with conventional oestrogen treatment.

The initial studies with oestrogen targeted delivery have recently been expanded to include an additional set of matched hormones. A conjugate of glucagon and thyroid hormone (T~3~) has been created to deliver T~3~ specifically to the liver and adipose tissue to improve lipid metabolism, lessen hepatic steatosis and lower body weight. Coordinated action of both hormones synergistically corrected dyslipidaemia and hepatic steatosis in obese and atherosclerotic mice \[[@CR98]\]. At the highest doses tested, the combined targeted therapy also decreased body weight. The glucagon-mediated delivery of T~3~ specifically to tissues expressing the GcgR also improved glucose homeostasis. This indicates the ability of T~3~ to override the diabetogenic liability of GcgR agonism, most notably by hepatic action. Importantly, as observed with targeted oestrogen therapy, glucagon delivery of T~3~ demonstrated less of the detrimental cardiovascular effects of thyroid hormone action \[[@CR98]\]. These preclinical observations in rodents promote continued study with the aim of translation to larger animals and specifically primates, the central focus being the quantification of therapeutic index when administered for sustained periods. Unlike the combinatorial therapy of G-protein-coupled receptor-based peptide dual agonists, such as GLP-1/glucagon, these peptidyl nuclear hormone conjugates require additional consideration for differential pharmacodynamics where time action for clearance of each activity is inherently dissimilar.

Perspective and future directions {#Sec6}
=================================

Development of the first GLP-1R/ GcgR co-agonists has prompted the search for novel multi-agonists of differentiated mechanisms that offer unprecedented potential in the treatment of obesity. Chemical refinement in numerous academic and commercial laboratories continues in the pursuit of optimal pharmaceutical properties. Biologically, the mechanistic underpinnings and subtleties of these novel therapeutics are just beginning to be fully understood, with species- and sex-specific differences remaining high priorities in continuing studies. Integrated preclinical studies combining targeted mouse mutagenesis with pharmacology employing chemically refined agents should accelerate our understanding of biological action. As a specific example: do these multi-agonists act simultaneously at multiple receptors residing at a single tissue or even a single cell? In addition, as with any emerging pharmacology, careful and continued analysis for potential adverse effects is required, especially as these therapies advance for treatments in genetically diverse patient populations. While designed to be more specific in action, there is always the theoretical prospect of reduced safety if an oncogenic precursor happens to express more than one of the responsive receptors. Similarly, immunogenic potential is an ever-present concern in macromolecular medicinal chemistry and dual agonists capable of simultaneously binding at more than one cellular site increase the risk of an immune response \[[@CR12]\].

Despite the associated risks, co- and multi-agonists herald the dawn of an era of more personalised metabolic medicine. An expanded portfolio of multi-agonists would allow physicians to tailor therapy that targets specific facets of metabolic disease. For example, GLP-1R/GIPR dual agonists seem preferential in treatment of modestly overweight individuals with diabetes, where the emphasis is on metabolic control with lesser requirement for body weight reduction. In contrast, individuals with dyslipidaemia or hepatic steatosis might benefit more from treatment with a glucagon/T~3~ conjugate where reductions in hepatic fat and circulating lipids are of primary importance. Finally, in obese diabetic individuals, the GLP-1R/GIPR/GcgR tri-agonist may be the most appropriate option, having the greatest potential to improve metabolism by weight-dependent and -independent mechanisms.

Beyond metabolic disease, these multifunctional agonists have the potential to treat diseases where targeted medicinal action is preferred over systematic administration, as demonstrated with the GLP-1/oestrogen conjugate. Similar combinations of active biological agents might minimise the unwanted cardiovascular effects of traditional small-molecule-based drugs or target anti-inflammatory pharmacology to only certain select tissues. In addition, certain diseases such as Allan-Herndon-Dudley syndrome arise from the absence of a single specific transporter. This disease is characterised by the lack of functional MCT8 transporters, which ferry T~3~ into the CNS. The use of conjugates such as GLP-1/T~3~ could serve as a 'Trojan horse' delivery system where internalisation through a functional GLP-1 receptor might deliver T~3~ to the brain, ameliorating the disease (and potentially other similar human genetic deficiencies).

The discovery of GLP-1R/GcgR dual agonists has provided a fresh medicinal approach and renewed hope that obesity and its associated abnormalities might be managed with medicines as opposed to surgical interventions. Whether the spectacular preclinical pharmacology of GLP-1R/GcgR co-agonists will translate through successful phase 3 registration trials is a question that will be answered in the coming years, but the pursuit of multifunctional, targeted therapeutics is destined to continue.
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BAT

:   Brown adipose tissue

CEX

:   C-terminal extension

CNS

:   Central nervous system

DIO

:   Diet-induced obese

DPP-IV

:   Dipeptidylpeptidase-IV

EMA

:   European Medicines Agency

FDA

:   Food and Drug Administration

GcgR

:   Glucagon receptor

GIP

:   Glucose-dependent insulinotropic polypeptide

GIPR

:   GIP receptor

GLP-1

:   Glucagon-like peptide 1

GLP-1R

:   GLP-1 receptor

OXM

:   Oxyntomodulin

PEG

:   Polyethylene glycol

STZ

:   Streptozotocin

T~3~

:   Thyroid hormone
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